Developing ASIC1-targeted therapeutic candidates for ischemic injury
A preclinical biotechnology company advancing differentiated peptide and formulation-based approaches for acute neurological and cardiovascular indications
Yatrex Pharmaceuticals is a preclinical biotechnology company focused on developing novel therapeutic candidates targeting acid-sensing ion channel 1 (ASIC1), a key mediator of tissue injury under ischemic and acidic conditions.
The company’s pipeline combines proprietary tricyclic poly-arginine peptides with formulation-driven repurposing strategies, designed to support translational progress toward IND-enabling development.
Targeted Biology
Focused on ASIC1-mediated injury mechanisms with strong biological and translational rationale in ischemic disease.
Differentiated Modalities
A multi-asset pipeline spanning novel polycyclic peptide architectures and injectable formulation strategies.
Translational Discipline
Preclinical programs structured around pharmacokinetics, functional efficacy, and regulatory-aligned development milestones.